Danish Medicines Council makes five recommendations after April meeting

The council has processed five drug applications at this month’s meeting, including proposals from Bristol Meyers Squibb and Novartis, which received thumbs-up for treatments for cancer and spinal arthritis, respectively. Sanofi’s application was rejected and Merck/Pfizer’s combination pitch was not approved, despite new data.

Photo: Stine Rasmussen/Ritzau Scanpix

Wednesday brought bad news for pharmaceutical firms Merck, Pfizer and Sanofi.

During its monthly meeting, members of the Danish Medicines Council debated an application from Merck and Pfizer, which had sought backing to use the former firm’s blockbuster drug Bavencio (avelumab) in combination with the latter’s Inlyta (axitinib) to treat kidney cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs